Adjusted green HPLC determination of nirmatrelvir and ritonavir in the new FDA approved co-packaged pharmaceutical dosage using supported computational calculations

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 2045-2322

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Adjusted green HPLC determination of nirmatrelvir and ritonavir in the new FDA approved co-packaged pharmaceutical dosage using supported computational calculations ; volume:13 ; number:1 ; day:4 ; month:1 ; year:2023 ; pages:1-10 ; date:12.2023
Scientific reports ; 13, Heft 1 (4.1.2023), 1-10, 12.2023

Creator: Imam, Mohamed S.
Batubara, Afnan S.
Gamal, Mohammed
Abdelazim, Ahmed H.
Almrasy, Ahmed A.
Ramzy, Sherif

Contributor: SpringerLink (Online service)

DOI: 10.1038/s41598-022-26944-y

URN: urn:nbn:de:101:1-2023031321141516456251

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:46 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Imam, Mohamed S.
Batubara, Afnan S.
Gamal, Mohammed
Abdelazim, Ahmed H.
Almrasy, Ahmed A.
Ramzy, Sherif
SpringerLink (Online service)

Other Objects (12)

Higher sensitive selective spectrofluorometric determination of ritonavir in the presence of nirmatrelvir: application to new FDA approved co-packaged COVID-19 pharmaceutical dosage and spiked human plasma

The First FDA-Approved Antibody-Drug Conjugate

Repurposing FDA-approved drugs for anti-aging therapies

A systematic analysis of FDA-approved anticancer drugs

Hochschulschrift

Evaluierung von FDA-approved Drugs gegen das Humane Cytomegalievirus

Synthesis of the First FDA-Approved HIV Protease Inhibitor

FDA‐approved drugs featuring macrocycles or medium‐sized rings

Hochschulschrift

Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus

FDA-approved disulfiram as a novel treatment for aggressive leukemia

Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics

Identification of FDA-approved drugs targeting the Farnesoid X Receptor

Eco-friendly four spectrophotometric approaches for the simultaneous determination of the recently FDA-approved combination, bupivacaine and meloxicam in pharmaceutical dosage forms

Higher sensitive selective spectrofluorometric determination of ritonavir in the presence of nirmatrelvir: application to new FDA approved co-packaged COVID-19 pharmaceutical dosage and spiked human plasma

The First FDA-Approved Antibody-Drug Conjugate

Repurposing FDA-approved drugs for anti-aging therapies

A systematic analysis of FDA-approved anticancer drugs

Hochschulschrift

Evaluierung von FDA-approved Drugs gegen das Humane Cytomegalievirus

Synthesis of the First FDA-Approved HIV Protease Inhibitor

FDA‐approved drugs featuring macrocycles or medium‐sized rings

Hochschulschrift

Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus

FDA-approved disulfiram as a novel treatment for aggressive leukemia

Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics

Identification of FDA-approved drugs targeting the Farnesoid X Receptor

Eco-friendly four spectrophotometric approaches for the simultaneous determination of the recently FDA-approved combination, bupivacaine and meloxicam in pharmaceutical dosage forms

Higher sensitive selective spectrofluorometric determination of ritonavir in the presence of nirmatrelvir: application to new FDA approved co-packaged COVID-19 pharmaceutical dosage and spiked human plasma

The First FDA-Approved Antibody-Drug Conjugate

Repurposing FDA-approved drugs for anti-aging therapies

A systematic analysis of FDA-approved anticancer drugs

Hochschulschrift

Evaluierung von FDA-approved Drugs gegen das Humane Cytomegalievirus

Synthesis of the First FDA-Approved HIV Protease Inhibitor

FDA‐approved drugs featuring macrocycles or medium‐sized rings

Hochschulschrift

Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus

FDA-approved disulfiram as a novel treatment for aggressive leukemia

Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics

Identification of FDA-approved drugs targeting the Farnesoid X Receptor

Eco-friendly four spectrophotometric approaches for the simultaneous determination of the recently FDA-approved combination, bupivacaine and meloxicam in pharmaceutical dosage forms

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Adjusted green HPLC determination of nirmatrelvir and ritonavir in the new FDA approved co-packaged pharmaceutical dosage using supported computational calculations

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Higher sensitive selective spectrofluorometric determination of ritonavir in the presence of nirmatrelvir: application to new FDA approved co-packaged COVID-19 pharmaceutical dosage and spiked human plasma

The First FDA-Approved Antibody-Drug Conjugate

Repurposing FDA-approved drugs for anti-aging therapies

A systematic analysis of FDA-approved anticancer drugs

Evaluierung von FDA-approved Drugs gegen das Humane Cytomegalievirus

Synthesis of the First FDA-Approved HIV Protease Inhibitor

FDA‐approved drugs featuring macrocycles or medium‐sized rings

Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus

FDA-approved disulfiram as a novel treatment for aggressive leukemia

Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics

Identification of FDA-approved drugs targeting the Farnesoid X Receptor

Eco-friendly four spectrophotometric approaches for the simultaneous determination of the recently FDA-approved combination, bupivacaine and meloxicam in pharmaceutical dosage forms

Higher sensitive selective spectrofluorometric determination of ritonavir in the presence of nirmatrelvir: application to new FDA approved co-packaged COVID-19 pharmaceutical dosage and spiked human plasma

The First FDA-Approved Antibody-Drug Conjugate

Repurposing FDA-approved drugs for anti-aging therapies

A systematic analysis of FDA-approved anticancer drugs

Evaluierung von FDA-approved Drugs gegen das Humane Cytomegalievirus

Synthesis of the First FDA-Approved HIV Protease Inhibitor

FDA‐approved drugs featuring macrocycles or medium‐sized rings

Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus

FDA-approved disulfiram as a novel treatment for aggressive leukemia

Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics

Identification of FDA-approved drugs targeting the Farnesoid X Receptor

Eco-friendly four spectrophotometric approaches for the simultaneous determination of the recently FDA-approved combination, bupivacaine and meloxicam in pharmaceutical dosage forms

Higher sensitive selective spectrofluorometric determination of ritonavir in the presence of nirmatrelvir: application to new FDA approved co-packaged COVID-19 pharmaceutical dosage and spiked human plasma

The First FDA-Approved Antibody-Drug Conjugate

Repurposing FDA-approved drugs for anti-aging therapies

A systematic analysis of FDA-approved anticancer drugs

Evaluierung von FDA-approved Drugs gegen das Humane Cytomegalievirus

Synthesis of the First FDA-Approved HIV Protease Inhibitor

FDA‐approved drugs featuring macrocycles or medium‐sized rings

Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus

FDA-approved disulfiram as a novel treatment for aggressive leukemia

Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics

Identification of FDA-approved drugs targeting the Farnesoid X Receptor

Eco-friendly four spectrophotometric approaches for the simultaneous determination of the recently FDA-approved combination, bupivacaine and meloxicam in pharmaceutical dosage forms

Related objects

Reset password